{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:48:59Z","timestamp":1790801339095,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10354-025-01108-5","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:27:29Z","timestamp":1756895249000},"page":"45-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type\u00a02 diabetes mellitus","Therapieergebnisse und Sicherheitsprofil von SGLT2-Inhibitoren versus GLP-1-Agonisten bei Diabetes mellitus Typ\u00a02"],"prefix":"10.1007","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6733-8311","authenticated-orcid":false,"given":"Aftab","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-1040","authenticated-orcid":false,"given":"Mohd","family":"Imran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6540-7966","authenticated-orcid":false,"given":"Zia","family":"ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8822-0427","authenticated-orcid":false,"given":"Biswa Mohan","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Kumar","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"issue":"10365","key":"1108_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad\u00a0E, Lim\u00a0S, Lamptey\u00a0R, Webb\u00a0DR, Davies\u00a0MJ. Type\u00a02 diabetes. Lancet. 2022;400(10365):1803\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(22)01655-5.","journal-title":"Lancet"},{"issue":"1","key":"1108_CR2","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(1):S17\u2013S38. https:\/\/doi.org\/10.2337\/dc22-S002.","journal-title":"Diabetes Care"},{"key":"1108_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho\u00a0NH, Shaw\u00a0JE, Karuranga\u00a0S, Huang\u00a0Y, da Rocha Fernandes\u00a0JD, Ohlrogge\u00a0A, et\u00a0al. IDF diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271\u201381. https:\/\/doi.org\/10.1016\/j.diabres.2018.02.023.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"1108_CR4","doi-asserted-by":"publisher","first-page":"e2004","DOI":"10.1002\/hsr2.2004","volume":"7","author":"MJ Hossain","year":"2024","unstructured":"Hossain\u00a0MJ, Al-Mamun\u00a0M, Islam\u00a0MR. Diabetes mellitus, the fastest growing global public health concern: early detection should be focused. Health Sci Rep. 2024;7(3):e2004. https:\/\/doi.org\/10.1002\/hsr2.2004.","journal-title":"Health Sci Rep"},{"key":"1108_CR5","doi-asserted-by":"publisher","first-page":"905538","DOI":"10.3389\/fendo.2022.905538","volume":"13","author":"R Zhu","year":"2022","unstructured":"Zhu\u00a0R, Zhou\u00a0S, Xia\u00a0L, Bao\u00a0X. Incidence, morbidity and years lived with disability due to type\u00a02 diabetes mellitus in 204 countries and territories: trends from 1990 to 2019. Front Endocrinol. 2022;13:905538. https:\/\/doi.org\/10.3389\/fendo.2022.905538.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1108_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi\u00a0SE, Bergenstal\u00a0RM, Buse\u00a0JB, Diamant\u00a0M, Ferrannini\u00a0E, Nauck\u00a0M, et\u00a0al. Management of hyperglycemia in type\u00a02 diabetes, 2015: a\u00a0patient-centered approach: update to a\u00a0position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139. https:\/\/doi.org\/10.2337\/dc14-2441.","journal-title":"Diabetes Care"},{"issue":"6","key":"1108_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1002\/med.21314","volume":"34","author":"P Malla","year":"2014","unstructured":"Malla\u00a0P, Kumar\u00a0R, Mahapatra\u00a0MK, Kumar\u00a0M. Ramping glucosuria for management of type\u00a02 diabetes mellitus: an emerging cynosure. Med Res Rev. 2014;34(6):1146\u201367. https:\/\/doi.org\/10.1002\/med.21314.","journal-title":"Med Res Rev"},{"issue":"3","key":"1108_CR8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","volume":"23","author":"MK Mahapatra","year":"2022","unstructured":"Mahapatra\u00a0MK, Karuppasamy\u00a0M, Sahoo\u00a0BM. Semaglutide, a\u00a0glucagon like peptide\u20111 receptor agonist with cardiovascular benefits for management of type\u00a02 diabetes. Rev Endocr Metab Disord. 2022;23(3):521\u201339. https:\/\/doi.org\/10.1007\/s11154-021-09699-1.","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"1108_CR9","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s11095-022-03302-1","volume":"39","author":"MK Mahapatra","year":"2022","unstructured":"Mahapatra\u00a0MK, Karuppasamy\u00a0M, Sahoo\u00a0BM. Therapeutic potential of semaglutide, a\u00a0newer GLP\u20111 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a\u00a0narrative review. Pharm Res. 2022;39(6):1233\u201348. https:\/\/doi.org\/10.1007\/s11095-022-03302-1.","journal-title":"Pharm Res"},{"key":"1108_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0025-7753(14)70107-1","volume":"143","author":"B Soldevila","year":"2014","unstructured":"Soldevila\u00a0B, Puig-Domingo\u00a0M. Safety and tolerability of GLP\u20111 receptor agonists. Med Clin (Barc). 2014;143:35\u201340. https:\/\/doi.org\/10.1016\/S0025-7753(14)70107-1.","journal-title":"Med Clin (Barc)"},{"issue":"4","key":"1108_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso\u00a0SP, Daniels\u00a0GH, Brown-Frandsen\u00a0K, Kristensen\u00a0P, Mann\u00a0JF, Nauck\u00a0MA, et\u00a0al. Liraglutide and cardiovascular outcomes in type\u00a02 diabetes. N\u00a0Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"22","key":"1108_CR12","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman\u00a0B, Wanner\u00a0C, Lachin\u00a0JM, Fitchett\u00a0D, Bluhmki\u00a0E, Hantel\u00a0S, et\u00a0al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N\u00a0Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"5","key":"1108_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/20009666.2018.1521245","volume":"8","author":"SR Shah","year":"2018","unstructured":"Shah\u00a0SR, Najim\u00a0NI, Abbasi\u00a0Z, Fatima\u00a0M, Jangda\u00a0AA, Shahnawaz\u00a0W, et\u00a0al. Canagliflozin and cardiovascular disease-results of the CANVAS trial. J\u00a0Community Hosp Intern Med Perspect. 2018;8(5):267\u20138. https:\/\/doi.org\/10.1080\/20009666.2018.1521245.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"1108_CR14","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3436269","author":"CK Kramer","year":"2019","unstructured":"Kramer\u00a0CK, Ye\u00a0C, Retnakaran\u00a0R. Comparison of new glucose-lowering drugs for primary and secondary prevention of cardiovascular disease in type\u00a02 diabetes: a\u00a0network meta-analysis of cardiovascular outcome trials. SSRN Journal. 2019; https:\/\/doi.org\/10.2139\/ssrn.3436269.","journal-title":"SSRN Journal"},{"issue":"9","key":"1108_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann\u00a0JFE, \u00d8rsted\u00a0DD, Brown-Frandsen\u00a0K, Marso\u00a0SP, Poulter\u00a0NR, Rasmussen\u00a0S, Torn\u00f8e\u00a0K, Zinman\u00a0B, Buse\u00a0JB, LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type\u00a02 diabetes. N\u00a0Engl J Med. 2017;377(9):839\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1616011.","journal-title":"N Engl J Med"},{"issue":"6","key":"1108_CR16","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s13300-018-0524-z","volume":"9","author":"B Zinman","year":"2018","unstructured":"Zinman\u00a0B, Nauck\u00a0MA, Bosch-Traberg\u00a0H, Frimer-Larsen\u00a0H, \u00d8rsted\u00a0DD, Buse\u00a0JB. Liraglutide and glycaemic outcomes in the LEADER trial. Diabetes Ther. 2018;9(6):2383\u201392. https:\/\/doi.org\/10.1007\/s13300-018-0524-z.","journal-title":"Diabetes Ther"},{"issue":"7","key":"1108_CR17","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","volume":"25","author":"DK McGuire","year":"2023","unstructured":"McGuire\u00a0DK, Busui\u00a0RP, Deanfield\u00a0J, Inzucchi\u00a0SE, Mann\u00a0JFE, Marx\u00a0N, Mulvagh\u00a0SL, Poulter\u00a0N, Engelmann\u00a0MDM, Hovingh\u00a0GK, Ripa\u00a0MS, Gislum\u00a0M, Brown-Frandsen\u00a0K, Buse\u00a0JB. Effects of oral semaglutide on cardiovascular outcomes in individuals with type\u00a02 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a\u00a0randomized trial. Diabetes Obes Metab. 2023;25(7):1932\u201341. https:\/\/doi.org\/10.1111\/dom.15058.","journal-title":"Diabetes Obes Metab"},{"key":"1108_CR18","unstructured":"American Diabetes Association. 85th\u00a0scientific sessions. Oral semaglutide significantly improves cardiovascular outcomes in individuals with type\u00a02 diabetes https:\/\/professional.diabetes.org\/sites\/dpro\/files\/2025-06\/ADA2025_SOULTrialPressRelease_FINAL.PDF.pdf."},{"key":"1108_CR19","doi-asserted-by":"publisher","first-page":"838277","DOI":"10.3389\/fphar.2022.838277","volume":"13","author":"C Li","year":"2022","unstructured":"Li\u00a0C, Luo\u00a0J, Jiang\u00a0M, Wang\u00a0K. The efficacy and safety of the combination therapy with GLP\u20111 receptor agonists and SGLT-2\u00a0inhibitors in type\u00a02 diabetes mellitus: a\u00a0systematic review and meta-analysis. Front Pharmacol. 2022;13:838277. https:\/\/doi.org\/10.3389\/fphar.2022.838277.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1108_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12020-019-02175-6","volume":"67","author":"M Guo","year":"2020","unstructured":"Guo\u00a0M, Gu\u00a0J, Teng\u00a0F, Chen\u00a0J, Ma\u00a0X, Chen\u00a0Q, et\u00a0al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP\u20111 receptor agonists in the treatment of type\u00a02 diabetes or obese adults: a\u00a0systematic review and meta-analysis. Endocrine. 2020;67(2):294\u2013304. https:\/\/doi.org\/10.1007\/s12020-019-02175-6.","journal-title":"Endocrine"},{"key":"1108_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker\u00a0TA, Wiviott\u00a0SD, Raz\u00a0I, et\u00a0al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type\u00a02 diabetes: a\u00a0systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31\u20139.","journal-title":"Lancet"},{"key":"1108_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar\u00a0N, Lee\u00a0MMY, Kristensen\u00a0SL, et\u00a0al. Cardiovascular, mortality, and kidney outcomes with GLP\u20111 receptor agonists in patients with type\u00a02 diabetes: a\u00a0systematic review and meta-analysis of randomized trials. Lancet Diabetes Endocrinol. 2021;9:653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1108_CR23","doi-asserted-by":"publisher","unstructured":"Apperloo\u00a0E, Neuen\u00a0BL, Fletcher\u00a0RA, et\u00a0al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a\u00a0SMART\u2011C collaborative meta-analysis of randomized controlled trials. Lancet Diabetes Endocrinol. 2024; https:\/\/doi.org\/10.1016\/S2213-8587(24)00155-4.","DOI":"10.1016\/S2213-8587(24)00155-4"},{"key":"1108_CR24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","volume":"82","author":"JS Neves","year":"2023","unstructured":"Neves\u00a0JS, Borges-Canha\u00a0M, Vasques-N\u00f3voa\u00a0F, et\u00a0al. GLP\u20111 receptor agonist therapy with and without SGLT2 inhibitors in patients with type\u00a02 diabetes. J\u00a0Am Coll Cardiol. 2023;82:517\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1108_CR25","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(24)00183-9","volume":"12","author":"CE Cervantes","year":"2024","unstructured":"Cervantes\u00a0CE. SGLT2 inhibitors and GLP\u20111 receptor agonists: the definitive combination? Lancet Diabetes Endocrinol. 2024;12(8):507\u20138.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1108_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.2337\/db24-0688","volume":"74","author":"Y Wang","year":"2025","unstructured":"Wang\u00a0Y, Xia\u00a0C, Li\u00a0M, Xu\u00a0G. Comparison of the effects of SGLT-2i versus GLP-1RA on cardiovascular and renal outcomes in patients with type\u00a02 diabetes, based on baseline renal function. Diabetes. 2025;74:672\u201381. https:\/\/doi.org\/10.2337\/db24-0688.","journal-title":"Diabetes"},{"issue":"1","key":"1108_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2337\/db25-898-P","volume":"74","author":"T Mori","year":"2025","unstructured":"Mori\u00a0T, Kuss\u00a0O, Mader\u00a0JK, Seufert\u00a0J, Holl\u00a0RW, Lanzinger\u00a0S, Grimsmann\u00a0JM. SGLT2 inhibitors or GLP\u20111 receptor agonists? Development of a\u00a0personalized treatment algorithm for individuals with type\u00a02 diabetes. Diabetes. 2025;74(1):898. https:\/\/doi.org\/10.2337\/db25-898-P.","journal-title":"Diabetes"},{"issue":"1","key":"1108_CR28","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48(1):S181\u2013S206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"key":"1108_CR29","doi-asserted-by":"publisher","first-page":"1011535","DOI":"10.3389\/fcvm.2022.1011535","volume":"9","author":"L Du","year":"2022","unstructured":"Du\u00a0L, Li\u00a0Z, Lan\u00a0P, Huang\u00a0H, Cheng\u00a0W. Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status. Front Cardiovasc Med. 2022;9:1011535. https:\/\/doi.org\/10.3389\/fcvm.2022.1011535.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1108_CR30","doi-asserted-by":"publisher","first-page":"e031805","DOI":"10.1161\/JAHA.123.031805","volume":"13","author":"R Kani","year":"2024","unstructured":"Kani\u00a0R, Watanabe\u00a0A, Miyamoto\u00a0Y, Ejiri\u00a0K, Iwagami\u00a0M, Takagi\u00a0H, Slipczuk\u00a0L, Tsugawa\u00a0Y, Aikawa\u00a0T, Kuno\u00a0T. Comparison of effectiveness among different sodium-glucose cotransoporter\u20112 inhibitors according to underlying conditions: a\u00a0network meta-analysis of randomized controlled trials. J\u00a0Am Heart Assoc. 2024;13(3):e31805. https:\/\/doi.org\/10.1161\/JAHA.123.031805.","journal-title":"J Am Heart Assoc"},{"key":"1108_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.diabres.2018.06.008","volume":"143","author":"AJ Scheen","year":"2018","unstructured":"Scheen\u00a0AJ. Cardiovascular outcome studies in type\u00a02 diabetes: comparison between SGLT2 inhibitors and GLP\u20111 receptor agonists. Diabetes Res Clin Pract. 2018;143:88\u2013100. https:\/\/doi.org\/10.1016\/j.diabres.2018.06.008.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1108_CR32","doi-asserted-by":"publisher","first-page":"e84137","DOI":"10.7759\/cureus.84137","volume":"17","author":"HU Khan","year":"2025","unstructured":"Khan\u00a0HU, Akhtar\u00a0B, Singla\u00a0B, Mughal\u00a0HMF, Hamid\u00a0A, Khan\u00a0ZU, Ismail\u00a0S, Sana\u00a0M, Khaliq\u00a0M. Comparative effectiveness of sodium-glucose cotransporter\u20112 inhibitors versus glucagon-like peptide\u20111 receptor agonists in reducing cardiovascular events in patients with type\u00a02 diabetes. Cureus. 2025;17(5):e84137. https:\/\/doi.org\/10.7759\/cureus.84137.","journal-title":"Cureus"},{"issue":"1","key":"1108_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-024-02150-0","volume":"23","author":"PT Htoo","year":"2024","unstructured":"Htoo\u00a0PT, Tesfaye\u00a0H, Schneeweiss\u00a0S, et\u00a0al. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide\u20111 receptor agonists: final-year results from the EMPRISE study. Cardiovasc Diabetol. 2024;23(1):57. https:\/\/doi.org\/10.1186\/s12933-024-02150-0.","journal-title":"Cardiovasc Diabetol"},{"key":"1108_CR34","unstructured":"EMPRISE: empagliflozin bests GLP\u20111 Ras, DPP\u20114 inhibitors for reducing heart failure hospitalizations https:\/\/www.hcplive.com\/view\/emprise-empagliflozin-bests-glp-1-ras-dpp-4-inhibitors-for-reducing-heart-failure-hospitalizations."},{"issue":"1","key":"1108_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"Yamada\u00a0T, Wakabayashi\u00a0M, Bhalla\u00a0A, Chopra\u00a0N, Miyashita\u00a0H, Mikami\u00a0T, et\u00a0al. Cardiovascular and renal outcomes with SGLT-2\u00a0inhibitors versus GLP\u20111 receptor agonists in patients with type\u00a02 diabetes mellitus and chronic kidney disease: a\u00a0systematic review and network meta-analysis. Cardiovasc Diabetol. 2021;20(1):14. https:\/\/doi.org\/10.1186\/s12933-020-01197-z.","journal-title":"Cardiovasc Diabetol"},{"key":"1108_CR36","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer\u00a0SC, Tendal\u00a0B, Mustafa\u00a0RA, Vandvik\u00a0PO, Li\u00a0S, Hao\u00a0Q, et\u00a0al. Sodium-glucose cotransporter protein\u20112 (SGLT-2) inhibitors and glucagon-like peptide\u20111 (GLP-1) receptor agonists for type\u00a02 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. https:\/\/doi.org\/10.1136\/bmj.m4573.","journal-title":"BMJ"},{"issue":"1","key":"1108_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher\u00a0D, Shamseer\u00a0L, Clarke\u00a0M, Ghersi\u00a0D, Liberati\u00a0A, Petticrew\u00a0M, et\u00a0al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"Syst Rev"},{"key":"1108_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","volume":"14","author":"AM Methley","year":"2014","unstructured":"Methley\u00a0AM, Campbell\u00a0S, Chew-Graham\u00a0C, McNally\u00a0R, Cheraghi-Sohi\u00a0S. PICO, PICOS and SPIDER: a\u00a0comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14:579. https:\/\/doi.org\/10.1186\/s12913-014-0579-0.","journal-title":"BMC Health Serv Res"},{"key":"1108_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK-L Lo","year":"2014","unstructured":"Lo\u00a0CK\u2011L, Mertz\u00a0D, Loeb\u00a0M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45. https:\/\/doi.org\/10.1186\/1471-2288-14-45.","journal-title":"BMC Med Res Methodol"},{"key":"1108_CR40","series-title":"Cochrane handbook for systematic reviews of interventions: Cochrane book series","first-page":"1","volume-title":"Assessing risk of bias in included studies","author":"JP Higgins","year":"2008","unstructured":"Higgins\u00a0JP, Altman\u00a0DG. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series. 2008. pp.\u00a01\u201373."},{"key":"1108_CR41","doi-asserted-by":"publisher","first-page":"e3971","DOI":"10.1136\/bmj.e3971","volume":"344","author":"P Sedgwick","year":"2012","unstructured":"Sedgwick\u00a0P. Meta-analyses: tests of heterogeneity. BMJ. 2012;344:e3971. https:\/\/doi.org\/10.1136\/bmj.e3971.","journal-title":"BMJ"},{"key":"1108_CR42","unstructured":"Deeks JJ, Higgins JP. Statistical algorithms in review manager 5. 2010. https:\/\/training.cochrane.org\/handbook\/statistical-methods-revman5."},{"issue":"8","key":"1108_CR43","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","volume":"84","author":"D Edmonston","year":"2024","unstructured":"Edmonston\u00a0D, Mulder\u00a0H, Lydon\u00a0E, Chiswell\u00a0K, Lampron\u00a0Z, Shay\u00a0C, et\u00a0al. Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP\u20111 receptor agonists in type\u00a02 diabetes. J\u00a0Am Coll Cardiol. 2024;84(8):696\u2013708. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.016.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1108_CR44","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie\u00a0Y, Bowe\u00a0B, Gibson\u00a0AK, McGill\u00a0JB, Maddukuri\u00a0G, Yan\u00a0Y, et\u00a0al. Comparative effectiveness of SGLT2 inhibitors, GLP\u20111 receptor agonists, DPP-4\u00a0inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a\u00a0target trial using health care databases. Diabetes Care. 2020;43(11):2859\u201369. https:\/\/doi.org\/10.2337\/dc20-1890.","journal-title":"Diabetes Care"},{"issue":"11","key":"1108_CR45","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.2337\/dc23-0671","volume":"46","author":"A Kutz","year":"2023","unstructured":"Kutz\u00a0A, Kim\u00a0DH, Wexler\u00a0DJ, Liu\u00a0J, Schneeweiss\u00a0S, Glynn\u00a0RJ, et\u00a0al. Comparative cardiovascular effectiveness and safety of SGLT-2\u00a0inhibitors, GLP\u20111 receptor agonists, and DPP-4\u00a0inhibitors according to frailty in type\u00a02 diabetes. Diabetes Care. 2023;46(11):2004\u201314. https:\/\/doi.org\/10.2337\/dc23-0671.","journal-title":"Diabetes Care"},{"issue":"1","key":"1108_CR46","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-022-01572-y","volume":"21","author":"M Baviera","year":"2022","unstructured":"Baviera\u00a0M, Foresta\u00a0A, Colacioppo\u00a0P, Macaluso\u00a0G, Roncaglioni\u00a0MC, Tettamanti\u00a0M, et\u00a0al. Effectiveness and safety of GLP\u20111 receptor agonists versus SGLT-2\u00a0inhibitors in type\u00a02 diabetes: an Italian cohort study. Cardiovasc Diabetol. 2022;21(1):162. https:\/\/doi.org\/10.1186\/s12933-022-01572-y.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1108_CR47","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00125-024-06251-z","volume":"67","author":"GP Fadini","year":"2024","unstructured":"Fadini\u00a0GP, Longato\u00a0E, Morieri\u00a0ML, Bonora\u00a0E, Consoli\u00a0A, Fattor\u00a0B, et\u00a0al. Comparative renal outcomes of matched cohorts of patients with type\u00a02 diabetes receiving SGLT2 inhibitors or GLP\u20111 receptor agonists under routine care. Diabetologia. 2024;67(11):2585\u201397. https:\/\/doi.org\/10.1007\/s00125-024-06251-z.","journal-title":"Diabetologia"},{"issue":"1","key":"1108_CR48","doi-asserted-by":"publisher","first-page":"e001451","DOI":"10.1136\/bmjdrc-2020-001451","volume":"8","author":"E Longato","year":"2020","unstructured":"Longato\u00a0E, Di Camillo\u00a0B, Sparacino\u00a0G, Gubian\u00a0L, Avogaro\u00a0A, Fadini\u00a0GP. Cardiovascular outcomes of type\u00a02 diabetic patients treated with SGLT-2\u00a0inhibitors versus GLP\u20111 receptor agonists in real-life. BMJ Open Diabetes Res Care. 2020;8(1):e1451. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001451.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"1108_CR49","doi-asserted-by":"publisher","first-page":"100621","DOI":"10.1016\/j.lanhl.2024.07.004","volume":"5","author":"F-Y Hsiao","year":"2024","unstructured":"Hsiao\u00a0F\u2011Y, Tan\u00a0EC\u2011H, Meng\u00a0L\u2011C, Lin\u00a0Y\u2011C, Chen\u00a0H\u2011M, Guan\u00a0S\u2011T, et\u00a0al. Effect of frailty on effectiveness and safety of GLP\u20111 receptor agonists versus SGLT2 inhibitors in people with type\u00a02 diabetes in Taiwan: a\u00a0retrospective, nationwide, longitudinal study. Lancet Healthy Longev. 2024;5(9):100621. https:\/\/doi.org\/10.1016\/j.lanhl.2024.07.004.","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"1108_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12933-021-01258-x","volume":"20","author":"M Lugner","year":"2021","unstructured":"Lugner\u00a0M, Sattar\u00a0N, Miftaraj\u00a0M, Ekelund\u00a0J, Franz\u00e9n\u00a0S, Svensson\u00a0A\u2011M, et\u00a0al. Cardiorenal and other diabetes related outcomes with SGLT-2\u00a0inhibitors compared to GLP\u20111 receptor agonists in type\u00a02 diabetes: nationwide observational study. Cardiovasc Diabetol. 2021;20(1):67. https:\/\/doi.org\/10.1186\/s12933-021-01258-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"1108_CR51","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/ehjcvp\/pvab053","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard\u00a0CH, Starkopf\u00a0L, Gerds\u00a0TA, Vestergaard\u00a0P, Bonde\u00a0AN, Fosb\u00f8l\u00a0E, et\u00a0al. Cardiovascular outcomes with GLP\u20111 receptor agonists vs. SGLT-2\u00a0inhibitors in patients with type\u00a02 diabetes. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):549\u201356. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab053.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"1108_CR52","doi-asserted-by":"publisher","first-page":"19351","DOI":"10.1038\/s41598-019-55524-w","volume":"9","author":"M Castellana","year":"2019","unstructured":"Castellana\u00a0M, Cignarelli\u00a0A, Brescia\u00a0F, Perrini\u00a0S, Natalicchio\u00a0A, Laviola\u00a0L, et\u00a0al. Efficacy and safety of GLP\u20111 receptor agonists as add-on to SGLT2 inhibitors in type\u00a02 diabetes mellitus: a\u00a0meta-analysis. Sci Rep. 2019;9(1):19351. https:\/\/doi.org\/10.1038\/s41598-019-55524-w.","journal-title":"Sci Rep"},{"issue":"8","key":"1108_CR53","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/dmrr.2810","volume":"32","author":"J Jendle","year":"2016","unstructured":"Jendle\u00a0J, Grunberger\u00a0G, Blevins\u00a0T, Giorgino\u00a0F, Hietpas\u00a0RT, Botros\u00a0FT. Efficacy and safety of dulaglutide in the treatment of type\u00a02 diabetes: a\u00a0comprehensive review of the dulaglutide clinical data focusing on the AWARD phase\u00a03 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776\u201390. https:\/\/doi.org\/10.1002\/dmrr.2810.","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"1108_CR54","doi-asserted-by":"publisher","first-page":"e1002983","DOI":"10.1371\/journal.pmed.1002983","volume":"16","author":"J Menne","year":"2019","unstructured":"Menne\u00a0J, Dumann\u00a0E, Haller\u00a0H, Schmidt\u00a0BM. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a\u00a0systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002983. https:\/\/doi.org\/10.1371\/journal.pmed.1002983.","journal-title":"PLoS Med"},{"issue":"6","key":"1108_CR55","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.amjms.2024.07.011","volume":"368","author":"A Tuersun","year":"2024","unstructured":"Tuersun\u00a0A, Hou\u00a0G, Cheng\u00a0G. Efficacy and safety of the combination or monotherapy with GLP\u20111 receptor agonists and SGLT-2\u00a0inhibitors in type\u00a02 diabetes mellitus: an update systematic review and meta-analysis. Am J Med Sci. 2024;368(6):579\u201388. https:\/\/doi.org\/10.1016\/j.amjms.2024.07.011.","journal-title":"Am J Med Sci"},{"issue":"10","key":"1108_CR56","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1111\/dom.14108","volume":"22","author":"C Mantsiou","year":"2020","unstructured":"Mantsiou\u00a0C, Karagiannis\u00a0T, Kakotrichi\u00a0P, Malandris\u00a0K, Avgerinos\u00a0I, Liakos\u00a0A, et\u00a0al. Glucagon-like peptide\u20111 receptor agonists and sodium-glucose co-transporter-2\u00a0inhibitors as combination therapy for type\u00a02 diabetes: a\u00a0systematic review and meta-analysis. Diabetes Obes Metab. 2020;22(10):1857\u201368. https:\/\/doi.org\/10.1111\/dom.14108.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1108_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/14740338.2018.1428305","volume":"17","author":"A Consoli","year":"2018","unstructured":"Consoli\u00a0A, Formoso\u00a0G, Baldassarre\u00a0MPA, Febo\u00a0F. A\u00a0comparative safety review between GLP\u20111 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf. 2018;17(3):293\u2013302. https:\/\/doi.org\/10.1080\/14740338.2018.1428305.","journal-title":"Expert Opin Drug Saf"},{"key":"1108_CR58","unstructured":"Khandker TA. Relationship between SGLT2 inhibitor use and risk of lower limb amputations: a\u00a0pharmacovigilance study: Brac University. 2023. https:\/\/dspace.bracu.ac.bd\/xmlui\/bitstream\/handle\/10361\/22046\/19146015_PHR.pdf?sequence=1&isAllowed=y."}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-025-01108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-025-01108-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-025-01108-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:04:16Z","timestamp":1773785056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-025-01108-5"}},"subtitle":["Systematic review of real-world observational studies","Systematische \u00dcbersichtsarbeit zu Beobachtungsstudien aus der Praxis"],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":58,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1108"],"URL":"https:\/\/doi.org\/10.1007\/s10354-025-01108-5","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Alam, M.\u00a0Imran, Z.\u00a0ur Rehman, B.M.\u00a0Sahoo and M.K.\u00a0Mahapatra declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}